Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.

Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Triple Negative Breast Cancer Foundation TNBC Is A, 53% OFF

Recent advances in targeted strategies for triple-negative breast

Triple negative breast cancer and non-small cell lung cancer

Frontiers Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities

Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Pharmaceutics, Free Full-Text

Sacituzumab Earns Regular FDA Approval For TNBC NCI

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Biomolecules, Free Full-Text

Breaking barriers in triple negative breast cancer (TNBC